Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2012 by West Coast Retina Medical Group, Inc..
Recruitment status was:  Active, not recruiting
Genentech, Inc.
Information provided by (Responsible Party):
Arthur D. Fu, MD, West Coast Retina Medical Group, Inc. Identifier:
First received: March 7, 2011
Last updated: February 24, 2012
Last verified: February 2012
To obtain a genotypic analysis of patients with chronic exudative age-related macular degeneration noted to have subretinal or intraretinal edema despite continuous monthly Anti-VEGF therapy.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Genotypic Evaluation of Chronic Exudative Macular Degeneration Despite Monthly Anti-Vascular Endothelial Growth Factor (VEGF) Therapy

Resource links provided by NLM:

Further study details as provided by West Coast Retina Medical Group, Inc.:

Primary Outcome Measures:
  • Genetic analysis of patients with chronic wet age-related macular degeneration despite continuous anti-VEGF treatment [ Time Frame: This is a one time only blood draw. ]

Secondary Outcome Measures:
  • To evaluate demographic and clinical characteristics in patients treated with anti-VEGF therapy who fail to respond completely. [ Time Frame: This is a one time only blood draw and assessment of clinical characteristics. ]

Estimated Enrollment: 40
Study Start Date: April 2011
Estimated Study Completion Date: June 2012
Estimated Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Wet AMD Non-Responders to Anti-VEGF


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients diagnosed with Wet Age-Related Macular Degeneration

Inclusion Criteria:

  • Ability to provide written informed consent for participation in this study
  • Subjects diagnoses of neovascular AMD who are on a monthly anti-VEGF regimen (have had >10 or more ranibizumab and/or bevacizumab injections within the last year) and who still have intra-retinal or subretinal fluid as confirmed by the Investigator

Exclusion Criteria:

  • Subjects with a Pigment Epithelial Detachment Exclusively
  • Subjects with Serous Pigment Epithelial Detachments
  • Subjects with history of the following:

idiopathic polypoidal choroidal vasculopathy

  • pathologic degenerative myopia
  • central serous chorioretinopathy
  • familial drusen
  • adult onset foveal pattern dystrophy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01310686

United States, California
West Coast Retina Medical Group, Inc.
San Francisco, California, United States, 94107
Sponsors and Collaborators
West Coast Retina Medical Group, Inc.
Genentech, Inc.
  More Information

Responsible Party: Arthur D. Fu, MD, Principal Investigator, West Coast Retina Medical Group, Inc. Identifier: NCT01310686     History of Changes
Other Study ID Numbers: FVF4990s
Study First Received: March 7, 2011
Last Updated: February 24, 2012

Keywords provided by West Coast Retina Medical Group, Inc.:
wet AMD anti-VEGF
Genetic analysis of patients with Wet AMD who have not responded fully to anti-VEGF treatments

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Endothelial Growth Factors
Growth Substances
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Inhibitors
Antineoplastic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on April 28, 2017